vs
RELMADA THERAPEUTICS, INC.（RLMD）与REZOLVE AI PLC（RZLV）财务数据对比。点击上方公司名可切换其他公司
RELMADA THERAPEUTICS, INC.的季度营收约是REZOLVE AI PLC的1.0倍（$1.3M vs $1.2M）
Relmada Therapeutics是一家临床阶段生物技术公司，专注于开发中枢神经系统疾病新型疗法，其核心在研产品针对难治性抑郁症，目前正推进临床试验，致力于满足北美、欧洲等主要市场未被覆盖的患者医疗需求。
REZOLVE AI PLC是总部位于英国的科技企业，开发人工智能驱动的移动互动与即时交易平台，支持用户直接从音频、视频、印刷内容中完成购买，服务欧洲、北美及部分亚太市场的零售、消费品与媒体客户。
RLMD vs RZLV — 直观对比
营收规模更大
RLMD
是对方的1.0倍
$1.2M
损益表 — Q4 FY2023 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3M | $1.2M |
| 净利润 | — | $-13.0M |
| 毛利率 | — | — |
| 营业利润率 | -2130.6% | -808.4% |
| 净利率 | — | -1078.8% |
| 营收同比 | 13.0% | — |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-0.84 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RLMDRZLV
| Q2 25 | — | $1.2M | ||
| Q4 23 | $1.3M | — | ||
| Q3 23 | $1.3M | — | ||
| Q2 23 | $1.4M | — | ||
| Q1 23 | $1.2M | — | ||
| Q4 22 | $1.1M | — | ||
| Q3 22 | $827.6K | — | ||
| Q2 22 | $387.3K | — |
净利润RLMDRZLV
| Q2 25 | — | $-13.0M | ||
| Q4 23 | — | — | ||
| Q3 23 | $-22.0M | — | ||
| Q2 23 | $-25.3M | — | ||
| Q1 23 | $-26.3M | — | ||
| Q4 22 | $-37.9M | — | ||
| Q3 22 | $-39.4M | — | ||
| Q2 22 | $-39.9M | — |
营业利润率RLMDRZLV
| Q2 25 | — | -808.4% | ||
| Q4 23 | -2130.6% | — | ||
| Q3 23 | -1717.3% | — | ||
| Q2 23 | -1908.9% | — | ||
| Q1 23 | -2331.3% | — | ||
| Q4 22 | -3472.5% | — | ||
| Q3 22 | -4680.6% | — | ||
| Q2 22 | -11750.1% | — |
净利率RLMDRZLV
| Q2 25 | — | -1078.8% | ||
| Q4 23 | — | — | ||
| Q3 23 | -1665.0% | — | ||
| Q2 23 | -1855.9% | — | ||
| Q1 23 | -2179.6% | — | ||
| Q4 22 | -3404.5% | — | ||
| Q3 22 | -4762.9% | — | ||
| Q2 22 | -10310.2% | — |
每股收益（稀释后）RLMDRZLV
| Q2 25 | — | — | ||
| Q4 23 | $-0.84 | — | ||
| Q3 23 | $-0.73 | — | ||
| Q2 23 | $-0.84 | — | ||
| Q1 23 | $-0.87 | — | ||
| Q4 22 | — | — | ||
| Q3 22 | $-1.31 | — | ||
| Q2 22 | $-1.33 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $96.3M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $85.4M | $-14.3M |
| 总资产 | $97.6M | $80.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RLMDRZLV
| Q2 25 | — | — | ||
| Q4 23 | $96.3M | — | ||
| Q3 23 | $106.3M | — | ||
| Q2 23 | $118.5M | — | ||
| Q1 23 | $132.4M | — | ||
| Q4 22 | $148.3M | — | ||
| Q3 22 | $141.6M | — | ||
| Q2 22 | $174.7M | — |
股东权益RLMDRZLV
| Q2 25 | — | $-14.3M | ||
| Q4 23 | $85.4M | — | ||
| Q3 23 | $100.7M | — | ||
| Q2 23 | $111.3M | — | ||
| Q1 23 | $125.5M | — | ||
| Q4 22 | $140.4M | — | ||
| Q3 22 | $166.3M | — | ||
| Q2 22 | $196.9M | — |
总资产RLMDRZLV
| Q2 25 | — | $80.1M | ||
| Q4 23 | $97.6M | — | ||
| Q3 23 | $109.1M | — | ||
| Q2 23 | $122.0M | — | ||
| Q1 23 | $135.6M | — | ||
| Q4 22 | $152.9M | — | ||
| Q3 22 | $187.1M | — | ||
| Q2 22 | $215.8M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-10.2M | $-4.9M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流RLMDRZLV
| Q2 25 | — | $-4.9M | ||
| Q4 23 | $-10.2M | — | ||
| Q3 23 | $-11.6M | — | ||
| Q2 23 | $-13.3M | — | ||
| Q1 23 | $-16.5M | — | ||
| Q4 22 | $-35.9M | — | ||
| Q3 22 | $-26.9M | — | ||
| Q2 22 | $-21.6M | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
